Risdiplam: First Approval
- PMID: 33044711
- DOI: 10.1007/s40265-020-01410-z
Risdiplam: First Approval
Abstract
Risdiplam (Evrysdi™) is an orally administered, survival motor neuron 2 (SMN2)-directed RNA splicing modifier being developed by Roche, PTC Therapeutics Inc and the SMA Foundation for the treatment of the spinal muscular atrophy. The small molecule is designed to treat spinal muscular atrophy caused by mutations in chromosome 5q leading to SMN protein deficiency. The drug boosts the ability of an alternative gene SMN2 to produce full-length and functional SMN protein. In August 2020, Evrysdi™ (risdiplam) received its first approval in the USA for the treatment of spinal muscular atrophy in patients 2 months of age and older. Risdiplam is in pre-registration for this indication in numerous countries worldwide, including the European Union, Brazil, Chile, China, Indonesia, Russia, South Korea and Taiwan. This article summarizes the milestones in the development of risdiplam leading to this first approval for spinal muscular atrophy.
Similar articles
-
[Risdiplam for the treatment of spinal muscular atrophy].Zh Nevrol Psikhiatr Im S S Korsakova. 2024;124(2):45-57. doi: 10.17116/jnevro202412402145. Zh Nevrol Psikhiatr Im S S Korsakova. 2024. PMID: 38465810 Russian.
-
Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs.Pharmacol Res Perspect. 2018 Nov 29;6(6):e00447. doi: 10.1002/prp2.447. eCollection 2018 Dec. Pharmacol Res Perspect. 2018. PMID: 30519476 Free PMC article.
-
The oral splicing modifier RG7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: Results from trials in healthy adults and patients with spinal muscular atrophy.Neuromuscul Disord. 2019 Jan;29(1):21-29. doi: 10.1016/j.nmd.2018.10.001. Epub 2018 Oct 30. Neuromuscul Disord. 2019. PMID: 30553700 Clinical Trial.
-
Risdiplam: A Review in Spinal Muscular Atrophy.CNS Drugs. 2022 Apr;36(4):401-410. doi: 10.1007/s40263-022-00910-8. Epub 2022 Mar 13. CNS Drugs. 2022. PMID: 35284988 Review.
-
Risdiplam: an investigational survival motor neuron 2 (SMN2) splicing modifier for spinal muscular atrophy (SMA).Expert Opin Investig Drugs. 2022 May;31(5):451-461. doi: 10.1080/13543784.2022.2056836. Epub 2022 Apr 11. Expert Opin Investig Drugs. 2022. PMID: 35316106 Review.
Cited by
-
Restoring Protein Expression in Neuromuscular Conditions: A Review Assessing the Current State of Exon Skipping/Inclusion and Gene Therapies for Duchenne Muscular Dystrophy and Spinal Muscular Atrophy.BioDrugs. 2021 Jul;35(4):389-399. doi: 10.1007/s40259-021-00486-7. Epub 2021 Jun 7. BioDrugs. 2021. PMID: 34097287 Review.
-
Oligonucleotide Therapeutics: From Discovery and Development to Patentability.Pharmaceutics. 2022 Jan 22;14(2):260. doi: 10.3390/pharmaceutics14020260. Pharmaceutics. 2022. PMID: 35213992 Free PMC article. Review.
-
Recombinant Adeno-Associated Virus Serotype 9 Gene Therapy in Spinal Muscular Atrophy.Front Neurol. 2021 Oct 13;12:726468. doi: 10.3389/fneur.2021.726468. eCollection 2021. Front Neurol. 2021. PMID: 34721262 Free PMC article. Review.
-
Small molecules modulating RNA splicing: a review of targets and future perspectives.RSC Med Chem. 2024 Jan 11;15(4):1109-1126. doi: 10.1039/d3md00685a. eCollection 2024 Apr 24. RSC Med Chem. 2024. PMID: 38665842 Free PMC article. Review.
-
Tumour microenvironment programming by an RNA-RNA-binding protein complex creates a druggable vulnerability in IDH-wild-type glioblastoma.Nat Cell Biol. 2024 Jun;26(6):1003-1018. doi: 10.1038/s41556-024-01428-5. Epub 2024 Jun 10. Nat Cell Biol. 2024. Retraction in: Nat Cell Biol. 2025 Jan 16. doi: 10.1038/s41556-025-01613-0. PMID: 38858501 Free PMC article. Retracted.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
